Research compound, not FDA-approved
Ipamorelin is sold as the cleanest growth hormone peptide. Its real history is an abandoned drug program.
Novo Nordisk designed it in the 1990s as NNC 26-0161. It reached two phase 2 trials for postoperative gut recovery: the published one failed its endpoint (p = 0.15) and the 320-patient one was never published. FDA now lists ipamorelin acetate in Category 2 of its compounding lists over significant safety concerns. We document the whole record: the real selectivity data at its true grade, every human trial, and the rodent studies the marketed benefits actually come from.
- 33fetch-verified citations, 100% peer-reviewed, government or registry
- 16studies in the graded evidence table, species labeled on every row
- 3of those rows are human: one PK study and the two failed-or-unpublished ileus trials
- 0human trials of the goals it is sold for: muscle, fat loss, anti-aging, recovery
Online care, from intake to delivery
Ipamorelin-based care, made simple
Choose your plan, complete a private medical intake, and connect with a licensed provider. If prescribed, treatment ships discreetly to your door.

Your care plan includes
Everything you need to get started
Important: Standalone ipamorelin is not sold through this checkout. The available option is a tesamorelin / ipamorelin blend.
Automatic refill is selected. After today, your plan renews automatically every month at $269.10 until canceled. You can turn off automatic refill above before continuing.
Encrypted checkout • provider review required • shipping included
- 01Choose your planSelect the supply and refill preference that works for you.
- 02Complete your intakeShare your health history in our private, secure flow.
- 03Provider reviewIf appropriate, your prescription is prepared and shipped.
Prescription treatment requires an online medical evaluation. A provider will determine whether treatment is medically appropriate; approval is not guaranteed. Checkout and medical intake are provided by FormBlends and its contracted clinical, pharmacy, payment, and fulfillment providers. Ipamorelin Co is the referring educational publisher and does not make prescribing decisions.
Key facts
- StatusResearch compound, not FDA-approved
- Clearance0.078 L/h/kg (IV, healthy men)
- Volume of distribution0.22 L/kg at steady state
- Gh peaksingle GH pulse peaking at 0.67 hours, then declining to negligible levels
- Dose proportionalitydose-proportional over 4.21 to 140.45 nmol/kg IV
- Animal kineticsrat: clearance 5-fold lower than GHRP-6, mainly intact urinary excretion, ~20% nasal bioavailability
- Unstudiedno published human subcutaneous or multiple-dose kinetics
- ClassGhrelin-receptor (GHS-R1a) agonist; GHRP-family pentapeptide
- Half-lifeabout 2 hours (human, IV) h
- OriginNovo Nordisk drug candidate NNC 26-0161 (1998)
- MoleculePentapeptide, C38H49N9O5, MW 711.9
- Human trials1 PK study; 2 phase 2 ileus trials (1 failed, 1 unpublished)
- Efficacy trials for marketed usesNone exist in humans
- WADAProhibited at all times (S2.2.4, named)
Browse by topic
Everything on Ipamorelin, organized the way you research it.
Free Ipamorelin tools
Practical calculators and references, each scoped and sourced.
study rows by species, from the evidence table


All guides
61 in-depth, individually cited guides.
Comparisons 17 guides
Evidence 15 guides
Dosing 12 guides
Sourcing 10 guides
Safety 7 guides


We will tell you if the evidence ever changes
One short email if something real happens: a new randomized trial, results posted for the 320-patient study, an FDA action. Nothing else.
